Plant Psychedelics
The most medically promising and the most physically dangerous psychedelic substance on this site. Ibogaine can interrupt opioid addiction in a single session — and it can also stop your heart. This is not a substance for unsupervised use. Period.
The Basics
Ibogaine is derived from the root bark of the West African shrub Tabernanthe iboga, used for centuries in Bwiti spiritual practice in Gabon and Cameroon. Its modern medical interest centers on a remarkable property: a single flood dose can dramatically reduce or eliminate opioid withdrawal symptoms and cravings, sometimes for months.
The experience itself is long (12–36 hours), intense, and often described as visionary rather than recreational — a panoramic life review, encounters with archetypal imagery, and deep psychological confrontation. It is nothing like psilocybin or LSD. Most people describe it as difficult, exhausting, and profoundly meaningful.
⚠ Cardiac toxicity — this is the critical risk
Ibogaine prolongs the QT interval — the electrical recovery phase of your heartbeat. This can trigger fatal cardiac arrhythmias (Torsades de Pointes). Deaths have occurred at ibogaine treatment centers, including in patients with no known pre-existing heart conditions. A recent EKG (within 2 weeks), liver function panel, and electrolyte panel are absolute minimums before any ibogaine session. This substance requires medical supervision. Home use at flood doses is reckless.
The Science
Ibogaine hits more receptor systems than almost any other psychoactive substance. This broad pharmacology is why it works on addiction — and why it's dangerous.
Opioid receptors
Ibogaine and its metabolite noribogaine bind to mu, kappa, and delta opioid receptors. Noribogaine persists in the body for weeks and may be responsible for sustained anti-craving effects long after the acute experience ends.
NMDA antagonism
Like ketamine, ibogaine blocks NMDA receptors. This may contribute to its anti-addictive properties and its dissociative visual effects. NMDA antagonism is a shared feature of several substances showing anti-addiction promise.
Serotonin transport
Ibogaine inhibits serotonin reuptake. This contributes to the mood effects and carries implications for drug interactions — combining with SSRIs or other serotonergic substances increases serotonin syndrome risk.
hERG channel blockade
This is the mechanism behind cardiac risk. Ibogaine blocks hERG potassium channels, prolonging the QT interval. This is the same mechanism that has pulled pharmaceutical drugs from the market. It's a serious, dose-dependent risk.
Harm Reduction
Ibogaine is not a substance for experimentation. It's a medical intervention that requires medical oversight. The information below is for people who are seriously considering ibogaine treatment for addiction, which is its primary modern use case.
Medical screening is non-negotiable. EKG within 2 weeks, liver function panel, complete metabolic panel, electrolyte levels. Any QT prolongation, liver impairment, or electrolyte imbalance is a contraindication. Facilities that skip screening are dangerous.
Cardiac monitoring during the session. Continuous EKG monitoring throughout the experience is the medical standard of care. Facilities without cardiac monitoring capability should be avoided.
Drug clearance before treatment. Opioids, stimulants, benzodiazepines, SSRIs, and many other substances must be cleared before ibogaine administration. Methadone requires an especially long clearance period (weeks, not days). Fentanyl's unpredictable tissue storage makes clearance timing difficult.
The experience is long and physically demanding. 12–36 hours of active effects, followed by days of recovery. Nausea, ataxia (loss of coordination), and sensitivity to light and sound are common. You will need support afterward.
Ibogaine interrupts addiction — it doesn't cure it. The window of reduced cravings it creates must be used for building new patterns, accessing therapy, and restructuring your life. Without follow-up support, relapse rates climb back up.
Clinic vetting matters enormously. Research the facility's medical staff, screening protocols, cardiac monitoring capability, emergency response plan, and aftercare program. Patient deaths have occurred at facilities with inadequate medical oversight.
Legal Landscape
Treatment Available
Mexico · Costa Rica · Brazil · New Zealand · Canada (Special Access Programme) · Several Caribbean nations · South Africa
Unregulated
Many countries have no specific ibogaine legislation · Gray market clinics operate in some jurisdictions · Quality and safety vary enormously
Illegal
United States (Schedule I) · France · Belgium · Denmark · Sweden · Switzerland · Poland
Tim's Take
[Tim's Take needed — your perspective on ibogaine's potential for addiction treatment, the cardiac risk reality, the ethics of underground providers, or the gap between its promise and its danger.]
If you or someone you know needs support
For substance use support, SAMHSA's helpline is available 24/7 at 1-800-662-4357 — free, confidential, and available in English and Spanish. The Fireside Project provides psychedelic-specific emotional support.
Fireside: Call or text · Available 24/7 · Free · Non-judgmental
Know Before You Go
Cardiac risk is real and fatal outcomes are documented. EKG screening and cardiac monitoring are non-negotiable.
This is not a home-use substance. Medical supervision is the minimum standard of care.
12–36 hours of active effects. Days of recovery. This is the most physically demanding psychedelic experience.
Ibogaine interrupts addiction — it doesn't cure it. Without follow-up support, the window closes.
Drug clearance is critical. Methadone requires weeks. Fentanyl clearance timing is unpredictable.
SAMHSA: 1-800-662-4357 · 24/7 · Free · Confidential